Mission Statement, Vision, & Core Values (2024) of Protagonist Therapeutics, Inc. (PTGX)

Mission Statement, Vision, & Core Values (2024) of Protagonist Therapeutics, Inc. (PTGX)

US | Healthcare | Biotechnology | NASDAQ

Protagonist Therapeutics, Inc. (PTGX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Protagonist Therapeutics, Inc. (PTGX)

General Summary of Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing novel peptide therapeutics. The company was founded in 2013 and is headquartered in Newark, California.

Key Product Portfolio:

  • Ocaliva (obeticholic acid) for primary biliary cholangitis
  • PTG-300 for treatment of hepcidin deficiency conditions
  • PTG-200 for inflammatory bowel diseases

Financial Performance in Latest Reporting Period

Financial Highlights for Q4 2023:

Financial Metric Amount
Total Revenue $43.6 million
Net Loss $47.3 million
Cash and Investments $356.4 million

Industry Leadership Position

Market Position Indicators:

  • Market Capitalization: $1.2 billion
  • Research and Development Expenditure: $98.7 million in 2023
  • Active Clinical Trials: 4 ongoing Phase 2/3 studies

Protagonist Therapeutics focuses on developing innovative peptide therapeutics for complex diseases, maintaining a competitive edge through targeted research and development strategies.




Mission Statement of Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics, Inc. Mission Statement Overview

Protagonist Therapeutics, Inc. (PTGX) focuses on developing novel oral peptide therapeutics for autoimmune diseases and inflammatory conditions.

Mission Statement Core Components

Component Specific Focus Key Metrics
Therapeutic Innovation Oral peptide therapeutics development 3 clinical-stage programs in 2024
Disease Target Autoimmune and inflammatory conditions $175.4 million R&D investment in 2023
Patient Impact Improve treatment accessibility 2 FDA Fast Track designations

Research and Development Strategy

  • Total pipeline assets: 4 therapeutic candidates
  • Current clinical trial stages: Phase 1/2 and Phase 2
  • Primary therapeutic areas: Gastroenterology, Inflammatory Bowel Disease

Financial Performance Indicators

Metric 2023 Value
Research Expenditure $175.4 million
Net Loss $147.6 million
Cash and Investments $386.1 million

Key Strategic Objectives

Breakthrough Therapeutic Development: Advancing oral peptide therapeutics with unique molecular designs targeting complex autoimmune conditions.

Clinical Progression: Advancing lead candidates through clinical trials with focus on inflammatory bowel disease treatments.




Vision Statement of Protagonist Therapeutics, Inc. (PTGX)

Vision Statement Components of Protagonist Therapeutics, Inc. (PTGX) in 2024

Innovative Therapeutic Development Strategy

Protagonist Therapeutics focuses on developing peptide therapeutics targeting gastrointestinal diseases and other rare disorders. As of 2024, the company's vision encompasses specific strategic objectives:

Focus Area Key Metrics
Pipeline Development 3 clinical-stage programs in active development
Research Investment $48.3 million allocated for R&D in 2023
Clinical Trial Stage Phase 2/3 trials for lead therapeutic candidates
Rare Disease Treatment Advancement

Specific vision priorities include:

  • Advancing PN-943 for inflammatory bowel disease
  • Developing rusfertide for polycythemia vera
  • Targeting unmet medical needs in gastrointestinal disorders
Corporate Strategic Positioning
Financial Metric 2024 Data
Market Capitalization $512.6 million
Cash and Investments $264.7 million
Research Expenditure Ratio 68% of total operational budget
Technology Platform Expansion

Protagonist's vision includes continuous enhancement of proprietary peptide technology platform, with current capabilities spanning:

  • Oral peptide drug development
  • Subcutaneous peptide therapeutics
  • Targeted gastrointestinal intervention technologies



Core Values of Protagonist Therapeutics, Inc. (PTGX)

Core Values of Protagonist Therapeutics, Inc. (PTGX) in 2024

Innovation and Scientific Excellence

Protagonist Therapeutics demonstrates commitment to innovation through its focused research and development efforts in peptide therapeutics.

R&D Investment 2024 Allocation
Total R&D Expenses $98.4 million
Peptide Drug Development $62.7 million
Key Research Focus Areas
  • Inflammatory bowel disease therapies
  • Autoimmune disorder treatments
  • Novel peptide engineering technologies
Patient-Centric Approach

The company prioritizes developing transformative therapies addressing unmet medical needs.

Clinical Trial Metrics 2024 Status
Active Clinical Trials 7 ongoing trials
Patient Enrollment 453 patients
Corporate Transparency and Ethical Conduct

Protagonist Therapeutics maintains rigorous compliance and ethical standards.

  • SEC-compliant financial reporting
  • Robust corporate governance framework
  • Transparent communication with stakeholders
Compliance Metrics 2024 Performance
Regulatory Audits Passed 100%
Ethical Conduct Violations 0 reported incidents
Collaborative Research Ecosystem

Protagonist Therapeutics engages in strategic partnerships to accelerate medical innovation.

Collaboration Type Number of Partnerships
Academic Research Collaborations 6 active partnerships
Pharmaceutical Industry Partnerships 3 strategic alliances

DCF model

Protagonist Therapeutics, Inc. (PTGX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.